PharmiWeb2h
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
News Medical9h
High HDL cholesterol may increase glaucoma risk in older adults
Good' (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
'Good' cholesterol may be linked to heightened glaucoma risk among over 55s
"Good" (HDL) cholesterol, usually considered to be beneficial for health, may be linked to a heightened risk of the serious ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
DVLA lists every condition you need to declare or face £1,000 fine
It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...
Pharm Exec14h
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Business Wire15h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Researchers probe potential role of Ozempic, other weight-loss drugs in vision loss
Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...